Yvonne L Eaglehouse1,2,3, Matthew W Georg1,3, Craig D Shriver1,2,4, Kangmin Zhu5,6,7,8. 1. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 2. Department of Surgery, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 3. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. 4. Walter Reed National Military Medical Center, Bethesda, MD, USA. 5. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. kzhu@murthacancercenter.org. 6. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA. kzhu@murthacancercenter.org. 7. Department of Preventive Medicine and Biostatistics; F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, MD, USA. kzhu@murthacancercenter.org. 8. Murtha Cancer Center Research Program, Uniformed Services University of the Health Sciences, 6720A Rockledge Drive, Suite 310, Bethesda, MD, 20817, USA. kzhu@murthacancercenter.org.
Abstract
PURPOSE: It is unclear whether time between breast cancer diagnosis and surgery is associated with survival and whether this relationship is affected by access to care. We evaluated the association between time-to-surgery and overall survival among women in the universal-access U.S. Military Health System (MHS). METHODS: Women aged 18-79 who received surgical treatment for stages I-III breast cancer between 1998 and 2010 were identified in linked cancer registry and administrative databases with follow-up through 2015. Multivariable Cox regression models were used to estimate risk of all-cause death associated with time-to-surgery intervals. RESULTS: The study included 9669 women with 93.1% survival during the study period. The hazards ratios (95% confidence intervals) of all-cause death associated with time-to-surgery were 1.15 (0.93, 1.42) for 0 days, 1.00 (reference) for 1-21 days, 0.97 (0.78, 1.21) for 22-35 days, and 1.30 (1.04, 1.61) for ≥ 36 days. The higher risk of mortality associated with time-to-surgery ≥ 36 days tended to be consistent when analyzed by surgery type, age at diagnosis, and tumor stage. CONCLUSIONS: In the MHS, longer time-to-surgery for breast cancer was associated with poorer overall survival, suggesting the importance of timeliness in receiving surgical treatment for breast cancer in relation to overall survival.
PURPOSE: It is unclear whether time between breast cancer diagnosis and surgery is associated with survival and whether this relationship is affected by access to care. We evaluated the association between time-to-surgery and overall survival among women in the universal-access U.S. Military Health System (MHS). METHODS:Women aged 18-79 who received surgical treatment for stages I-III breast cancer between 1998 and 2010 were identified in linked cancer registry and administrative databases with follow-up through 2015. Multivariable Cox regression models were used to estimate risk of all-cause death associated with time-to-surgery intervals. RESULTS: The study included 9669 women with 93.1% survival during the study period. The hazards ratios (95% confidence intervals) of all-cause death associated with time-to-surgery were 1.15 (0.93, 1.42) for 0 days, 1.00 (reference) for 1-21 days, 0.97 (0.78, 1.21) for 22-35 days, and 1.30 (1.04, 1.61) for ≥ 36 days. The higher risk of mortality associated with time-to-surgery ≥ 36 days tended to be consistent when analyzed by surgery type, age at diagnosis, and tumor stage. CONCLUSIONS: In the MHS, longer time-to-surgery for breast cancer was associated with poorer overall survival, suggesting the importance of timeliness in receiving surgical treatment for breast cancer in relation to overall survival.
Entities:
Keywords:
Breast surgery; Clinical outcomes; Lumpectomy; Mastectomy; Overall survival
Authors: Yvonne L Eaglehouse; Amie B Park; Matthew W Georg; Derek W Brown; Jie Lin; Stephanie Shao; Julie A Bytnar; Craig D Shriver; Kangmin Zhu Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Catherine Duggan; Allison Dvaladze; Anne F Rositch; Ophira Ginsburg; Cheng-Har Yip; Susan Horton; Rolando Camacho Rodriguez; Alexandru Eniu; Miriam Mutebi; Jean-Marc Bourque; Shahla Masood; Karla Unger-Saldaña; Anna Cabanes; Robert W Carlson; Julie R Gralow; Benjamin O Anderson Journal: Cancer Date: 2020-05-15 Impact factor: 6.860
Authors: M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte Journal: BMC Surg Date: 2021-12-07 Impact factor: 2.102
Authors: Timothy P Hanna; Will D King; Stephane Thibodeau; Matthew Jalink; Gregory A Paulin; Elizabeth Harvey-Jones; Dylan E O'Sullivan; Christopher M Booth; Richard Sullivan; Ajay Aggarwal Journal: BMJ Date: 2020-11-04